Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

Heart Failure Reviews

Volumn 18, Issue 2, 2013, Pages 107-122

  Gheorghiade, Mihai ^a   Vaduganathan, Muthiah ^b   Ambrosy, Andrew ^c   Böhm, Michael ^d   Campia, Umberto ^a   Cleland, John G F ^e   Fedele, Francesco ^f   Fonarow, Gregg C ^g   Maggioni, Aldo P ^h   Mebazaa, Alexandre ⁱ   Mehra, Mandeep ^j   Metra, Marco ^k   Nodari, Savina ^k   Pang, Peter S ^a   Ponikowski, Piotr ^l   Sabbah, Hani N ^m   Komajda, Michel ⁿ   Butler, Javed ^o  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF HULL   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UCLA MEDICAL CENTER   (United States)

^h ANMCO RESEARCH CENTER   (Italy)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k University and Civil Hospital of Brescia   (Italy)

^l WROCLAW MEDICAL UNIVERSITY   (Poland)

^m HENRY FORD HOSPITAL   (United States)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Blood pressure; Epidemiology; Heart failure; Hemodynamics; Outcomes

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; INOTROPIC AGENT; LEVOSIMENDAN; NITRATE;

ARTICLE; CARDIORENAL SYNDROME; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFECT; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING;

AGED; BLOOD PRESSURE; COMORBIDITY; CONGRESSES AS TOPIC; DISEASE MANAGEMENT; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PROGNOSIS; ROME; TREATMENT OUTCOME;

EID: 84879464098     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-012-9315-1     Document Type: Article

References (109)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y (2009) Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3):480-486. doi: 10.1161/CIRCULATIONAHA.108.191259
2. Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96(6A):5G-10G. doi: 10.1016/j.amjcard.2005.07. 015 (Pubitemid 41338069)
3. Jencks SF, Williams MV, Coleman EA (2009) Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 360(14):1418-1428. doi: 10.1056/NEJMsa0803563
4. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW (2007) Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 153(6):1021-1028. doi: 10.1016/j.ahj.2007.03.012 (Pubitemid 46809844)
5. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC (2007) Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 154(2):277, e271-e278. doi: 10.1016/j.ahj.2007.05.001 (Pubitemid 47069142)
6. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L (2010) Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 12(3):239-248. doi: 10.1093/eurjhf/hfq002
7. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M (2010) Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 3(2):314-325. doi: 10.1161/CIRCHEARTFAILURE.109.893222
8. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18):2217-2226. doi: 10.1001/jama.296.18.2217 (Pubitemid 44708052)
9. Tavazzi L, Maggioni AP, Lucci D, Cacciatore G, Ansalone G, Oliva F, Porcu M (2006) Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 27(10):1207-1215. doi: 10.1093/eurheartj/ehi845
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933-989. doi: 10.1016/j.ejheart.2008.08.005
11. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12(5):423-433. doi: 10.1093/eurjhf/hfq045
12. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153(1):98-104. doi: 10.1016/j.ahj.2006.09.005 (Pubitemid 44880871)
13. Thackray S, Easthaugh J, Freemantle N, Cleland JG (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail 4(4):515-529 (Pubitemid 36564973)
14. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41(6):997-1003 (Pubitemid 36315544)
15. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM (1999) Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 340(15):1162-1168. doi: 10.1056/NEJM199904153401504 (Pubitemid 29177875)
16. Reynolds HR, Hochman JS (2008) Cardiogenic shock: current concepts and improving outcomes. Circulation 117(5):686-697. doi: 10.1161/CIRCULATIONAHA.106. 613596
17. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16):1963-1971. doi: 10.1001/jama.291.16.1963 (Pubitemid 38544277)
18. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319-1331. doi: 10.1001/jama.297.12.1319 (Pubitemid 46513233)
19. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L (2010) EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12(10):1076-1084. doi: 10.1093/eurjhf/hfq154
20. Gheorghiade M, Braunwald E (2011) A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 305(16):1702-1703. doi: 10.1001/jama.2011.515
21. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112(25):3958-3968. doi: 10.1161/CIRCULATIONAHA.105.590091 (Pubitemid 43739494)
22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53(15):e1-e90. doi: 10.1016/j.jacc.2008.11.013
23. Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52(6):428-434 (Pubitemid 352040814)
24. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Pina I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M (2010) Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 159(5):841-849, e841. doi: 10.1016/j.ahj.2010.02.023
25. Cheng RK, Horwich TB, Fonarow GC (2008) Relation of systolic blood pressure to survival in both ischemic and nonischemic systolic heart failure. Am J Cardiol 102(12):1698-1705. doi: 10.1016/j.amjcard.2008.07.058
26. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293(5):572-580. doi: 10.1001/jama.293.5.572 (Pubitemid 40171239)
27. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F (2011) A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. doi: 10.1007/s10741-011-9280-0
28. Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr, Gheorghiade M, O'Connor CM (2004) Risk stratification after hospitalization for decompensated heart failure. J Card Fail 10(6):460-466
29. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290(19):2581-2587. doi: 10.1001/jama.290.19.2581 (Pubitemid 37443288)
30. Lee DS, Ghosh N, Floras JS, Newton GE, Austin PC, Wang X, Liu PP, Stukel TA, Tu JV (2009) Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail 2(6):616-623. doi: 10.1161/CIRCHEARTFAILURE.109.869743
31. Gheorghiade M, Peterson ED (2011) Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. JAMA 305(23):2456-2457. doi: 10.1001/jama.2011.836
32. Gheorghiade M, Filippatos G, De Luca L, Burnett J (2006) Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 119(12 Suppl 1):S3-S10. doi: 10.1016/j.amjmed.2006.09.011 (Pubitemid 44755377)
33. Kono T, Sabbah HN, Stein PD, Brymer JF, Khaja F (1991) Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 68(4):355-359
34. Sabbah HN, Kono T, Rosman H, Jafri S, Stein PD, Goldstein S (1992) Left ventricular shape: a factor in the etiology of functional mitral regurgitation in heart failure. Am Heart J 123(4 Pt 1):961-966
35. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S (1992) Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 20(7):1594-1598 (Pubitemid 23007515)
36. Sabbah HN, Kono T, Stein PD, Mancini GB, Goldstein S (1992) Left ventricular shape changes during the course of evolving heart failure. Am J Physiol 263(1 Pt 2):H266-H270
37. Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, Bonow RO, Gheorghiade M (2008) Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol 52(1):13-16. doi: 10.1016/j.jacc.2008.03.037 (Pubitemid 351852938)
38. Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, Liu PP, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghiade M (2009) Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 53(3):254-263. doi: 10.1016/j.jacc.2008.08.072
39. Gheorghiade M, Gattis Stough W, Adams KF Jr, Jaffe AS, Hasselblad V, O'Connor CM (2005) The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 96(6A):18G-25G. doi: 10.1016/j.amjcard.2005.07.017 (Pubitemid 41338070)
40. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS (2005) Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96(6A):11G-17G
41. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM (2010) Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 56(14):1071-1078. doi: 10.1016/j.jacc.2010.06. 016
42. O'Connor CM, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, Cleland J, Bloomfield D, Dittrich HC, Delucca P, Givertz MM, Mansoor G, Ponikowski P, Teerlink JR, Voors AA, Massie BM, Cotter G, Metra M (2011) Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. Circ Heart Fail 4(6):724-732. doi: 10.1161/CIRCHEARTFAILURE.111.961581
43. Schulz R, Rose J, Martin C, Brodde OE, Heusch G (1993) Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 88(2):684-695 (Pubitemid 23228069)
44. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289(2):194-202 (Pubitemid 36068707)
45. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209-216. doi: 10.1016/j.ahj.2004.08.005 (Pubitemid 40348525)
46. Forrester JS, Diamond G, Chatterjee K, Swan HJ (1976) Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 295(25):1404-1413. doi: 10.1056/NEJM197612162952505 (Pubitemid 8004135)
47. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57(22):2233-2241. doi: 10.1016/j.jacc.2010.10.065
48. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53(7):589-596. doi: 10.1016/j.jacc.2008.05.068
49. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M (2011) Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 32(20):2563-2572. doi: 10.1093/eurheartj/ehr238
50. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 94(7):957-960. doi: 10.1016/j.amjcard.2004.06.041 (Pubitemid 39349569)
51. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43(1):61-67 (Pubitemid 38045917)
52. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM (2002) The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8(3):136-141 (Pubitemid 34857278)
53. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM (2003) Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 9(1):13-25. doi: 10.1054/jcaf.2003.3 (Pubitemid 36356697)
54. Gheorghiade M, Bonow RO (1998) Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97(3):282-289 (Pubitemid 28067315)
55. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO (2006) Navigating the crossroads of coronary artery disease and heart failure. Circulation 114(11):1202-1213. doi: 10.1161/CIRCULATIONAHA.106.623199 (Pubitemid 44386485)
56. Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96(6A):47G-58G. doi: 10.1016/j.amjcard.2005.07.021 (Pubitemid 41338074)
57. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A (2003) Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362(9377):14-21 (Pubitemid 36840896)
58. Schulz R, Guth BD, Pieper K, Martin C, Heusch G (1992) Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation. Circ Res 70(6):1282-1295
59. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, Cotter G (2011) Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. doi: 10.1007/s10741-011-9261-3
60. Gheorghiade M, Pang PS (2009) Acute heart failure syndromes. J Am Coll Cardiol 53(7):557-573. doi: 10.1016/j.jacc.2008.10.041
61. Harinstein ME, Flaherty JD, Fonarow GC, Mehra MR, Lang RM, Kim RJ, Cleland JG, Knight BP, Pang PS, Bonow RO, Gheorghiade M (2011) Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart 97(19):1607-1618. doi: 10.1136/hrt.2011. 222331
62. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J (2010) National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol 56(5):343-351. doi: 10.1016/j.jacc.2010.03.051
63. Collins S, Storrow AB, Kirk JD, Pang PS, Diercks DB, Gheorghiade M (2008) Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. Ann Emerg Med 51(1):45-57. doi: 10.1016/j.annemergmed.2007.07.007 (Pubitemid 350309458)
64. Collins SP, Lindsell CJ, Storrow AB, Fermann GJ, Levy PD, Pang PS, Weintraub N, Frank Peacock W, Sawyer DB, Gheorghiade M (2011) Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy. Heart Fail Rev. doi: 10.1007/s10741-011-9294-7
65. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37(2):290-301. doi: 10.1007/s00134-010-2073-4
66. Mebazaa A (2009) Current ESC/ESICM and ACCF/AHA guidelines for the diagnosis and management of acute heart failure in adults - are there differences? Pol Arch Med Wewn 119(9):569-573
67. Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Butler J (2012) Echocardiographic evaluation of left ventricular structure and function: new modalities and potential applications in clinical trials. J Card Fail 18(2):159-172. doi: 10.1016/j.cardfail.2011.10.019
68. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Pina I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M (2010) Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 159(5):841-849, e841. doi: 10.1016/j.ahj.2010.02.023
69. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, Yancy CW, Young JB, Davidson CJ, Gheorghiade M (2008) Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Eur J Heart Fail 10(12):1215-1223. doi: 10.1016/j.ejheart.2008.09.009
70. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L (2000) Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102(6):611-616 (Pubitemid 30640659)
71. Writing Committee Members, Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391-e479. doi: 10.1161/circulationaha.109. 192065
72. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ Jr, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA (1996) The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 276(11):889-897 (Pubitemid 26301608)
73. Ruggenenti P, Remuzzi G (2011) Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. Eur Heart J 32(20):2476-2478. doi: 10.1093/eurheartj/ehr242
74. Metra M, Gheorghiade M, Bonow RO, Dei Cas L (2010) Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 122(18):1782-1785. doi: 10.1161/CIRCULATIONAHA.110.982207
75. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M (2008) Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299(22):2656-2666. doi: 10.1001/jama.299.22.2656 (Pubitemid 351831595)
76. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB (2007) Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med 167(14):1493-1502. doi: 10.1001/archinte.167.14.1493 (Pubitemid 47134697)
77. Stevenson LW (1999) Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1(3):251-257 (Pubitemid 30129393)
78. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN (2008) Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51(23):2276-2285. doi: 10.1016/j.jacc.2008.03.015
79. Gheorghiade M, Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302(19):2146-2147. doi: 10.1001/jama.2009.1657
80. Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96(6A):47G-58G. doi: 10.1016/j.amjcard.2005.07.021 (Pubitemid 41338074)
81. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138(1 Pt 1):78-86 (Pubitemid 29331125)
82. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH (2008) Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52(3):200-207. doi: 10.1016/j.jacc.2008.02.083 (Pubitemid 351915785)
83. Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, Taylor DO, Tang WH (2009) Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol 103(8):1113-1119. doi: 10.1016/j.amjcard.2008.12.028
84. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010) HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16(6):e1-e194. doi: 10.1016/j.cardfail.2010.04.004
85. De Luca L, Fonarow GC, Mebazaa A, Shin DD, Collins SP, Swedberg K, Gheorghiade M (2007) Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials. Acute Card Care 9(1):10-21. doi: 10.1080/17482940601134487 (Pubitemid 46622766)
86. De Luca L, Mebazaa A, Filippatos G, Parissis JT, Bohm M, Voors AA, Nieminen M, Zannad F, Rhodes A, El-Banayosy A, Dickstein K, Gheorghiade M (2008) Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 10(2):201-213. doi: 10.1016/j.ejheart.2008.01.002 (Pubitemid 351227429)
87. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO (2000) Current medical therapy for advanced heart failure. Heart Lung 29(1):16-32 (Pubitemid 30075567)
88. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12):1541-1547 (Pubitemid 34269999)
89. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12):1541-1547 (Pubitemid 34269999)
90. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328):196-202 (Pubitemid 34804646)
91. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297(17):1883-1891. doi: 10.1001/jama.297.17.1883 (Pubitemid 46707842)
92. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46(1):57-64. doi: 10.1016/j.jacc.2005.03.051 (Pubitemid 40905130)
93. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D (1996) Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279(1):120-127 (Pubitemid 27166902)
94. Guth BD, Schulz R, Heusch G (1993) Time course and mechanisms of contractile dysfunction during acute myocardial ischemia. Circulation 87(5 Suppl):IV35-IV42 (Pubitemid 23135648)
95. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, Alexander RW, et al. (1990) Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81(3):772-779 (Pubitemid 20090372)
96. Unverferth DV, Magorien RD, Lewis RP, Leier CV (1983) The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 105(1):176-179 (Pubitemid 13223495)
97. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, van Gilst WH, Crijns HJ (2000) Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35(1):19-28 (Pubitemid 30061254)
98. Gupta RC, Shimoyama H, Tanimura M, Nair R, Lesch M, Sabbah HN (1997) SR Ca(2+)-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol 273(1 Pt 2):H12-H18
99. Gupta RC, Mishra S, Rastogi S, Sharov VG, Sabbah HN (2005) Improvement of cardiac sarcoplasmic reticulum calcium cycling in dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device. Heart Fail Rev 10(2):149-155. doi: 10.1007/s10741-005-4642-0 (Pubitemid 41670329)
100. Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Grzybowski J, Valentini G, Sabbah HN, Gheorghiade M (2009) Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J 157(6):1035-1041. doi: 10.1016/j.ahj.2009.03.007
101. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS (2005) Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96(6A):11G-17G
102. Gheorghiade M, Sabbah HN (2007) Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes. Am J Cardiol 99(2A):1A-3A. doi: 10.1016/j.amjcard.2006.09.001 (Pubitemid 46096879)
103. Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M (2007) Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99(2A):41A-46A. doi: 10.1016/j.amjcard.2006.09.005 (Pubitemid 46096882)
104. Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M (2009) Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 14(4):277-287. doi: 10.1007/s10741-009-9136-z
105. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN (2008) Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51(23):2276-2285. doi: 10.1016/j.jacc.2008.03.015
106. Gheorghiade M, Ambrosy AP, Ferrandi M, Ferrari P (2011) Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med 12(63):141-151
107. Ghali JK, Smith WB, Torre-Amione G, Haynos W, Rayburn BK, Amato A, Zhang D, Cowart D, Valentini G, Carminati P, Gheorghiade M (2007) A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 99(2A):47A-56A. doi: 10.1016/j.amjcard.2006.09.006 (Pubitemid 46096883)
108. Campia U, Nodari S, Gheorghiade M (2010) Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Curr Heart Fail Rep 7(3):100-109. doi: 10.1007/s11897-010-0021-9
109. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, Gheorghiade M (2007) Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99(2A):4A-23A. doi: 10.1016/j.amjcard.2006.11.025 (Pubitemid 46099035)